Piramal Pharma Ltd - 543635 - Intimation - Details Of Litigation As Required Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations')
Details of Litigation as required under Regualtion 30 of the SEBI(Listing Obligations and Disclsoure Requirements) Regulations, 2015 ("SEBI Listing Regulations")
Piramal Pharma to see 13% CAGR in revenue, 40% in Ebitda in FY23-26: Jefferies
Investment banking firm expects pharma major's revenue to reach Rs 10,164.6 crore by FY26 Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Piramal Pharma Ltd - 543635 - Details Of Litigation As Required Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations')
Details of Litigation as required under Regulation 30 of the SEBI (LIsting Obligations and Disclsoure Requirements) Regualtions, 2015 ("SEBI Listing Regulations")
Piramal Pharma up almost 4% as US FDA closes inspection at Bethlehem plant
The US FDA conducted a Good Manufacturing Practices (GMP) Inspection of Piramal Pharma Limited's Bethlehem facility from 18th September 2023 to 27th September 2023. Piramal Pharma Ltd - 543635 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Successful Closure Of US FDA Inspection At Piramal Pharma'S Manufacturing Facility Located At Bethlehem, USA
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regualtions, 2015 - Successful Closure of US FDA Inspection at Piramal Pharma''s manufacturing facility located at Bethlehem, USA. Recovery and turnaround this year - Piramal Pharma Chairperson
Sustainability, besides quality and compliance adds edge to CDM business Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015